Macular Amyloidosis Diagnosis and Treatment in London

What is macular amyloidosis?

Macular amyloidosis (MA) is a type of primary cutaneous amyloidosis, meaning that the abnormal protein known as amyloid deposits in the skin without systemic organ involvement. These deposits are formed by fragments of keratinocytes – the cells of the outer skin layer – which become misfolded and accumulate in the dermis. The condition produces brownish, reticulated or rippled pigmentation, often compared to a “salt and pepper” or “rippled” pattern. Synonyms sometimes used include follicular keratosis with amyloid deposition, amyloidosis cutis dyschromica (related variant), and, in some cases, overlap with lichen amyloidosis.

Causes and risk factors

The exact cause is not fully understood, but macular amyloidosis develops when keratinocyte-derived proteins misfold and deposit in the upper dermis. Chronic friction and rubbing, particularly from coarse fabrics, back-scratchers, or habitual scratching, play a significant role. Genetic predisposition is also important, with higher prevalence reported in certain populations, especially in Asia, the Middle East, and South America.

Other risk factors include:

• Female sex – women are more frequently affected.
• Onset usually in early adulthood to middle age.
• Underlying atopic dermatitis or chronic pruritus increasing scratching behaviour.
• Family history of primary cutaneous amyloidosis.
• Environmental exposures such as sun damage may worsen pigmentation.

Symptoms and appearance

Patients typically present with itchy brown or grey-brown macules that merge into reticulated patches. The pigmentation has a characteristic rippled or “tortoiseshell” pattern, especially visible under bright light. Lesions are usually distributed symmetrically on the:

• Upper back
• Shoulders
• Chest
• Extensor arms

Unlike lichen amyloidosis, which produces raised, hyperkeratotic papules, macular amyloidosis is flat and macular. However, the two can overlap, producing a mixed form called biphasic amyloidosis.

Diagnosis

Diagnosis is primarily clinical, based on the characteristic appearance of rippled pigmentation in classical areas. Dermoscopy often shows a central white or grey hub with surrounding brown pigmentation in a reticulated pattern. In uncertain cases, a skin biopsy may be performed, demonstrating amyloid deposits in the papillary dermis highlighted by special stains such as Congo red or crystal violet.

Other conditions that may mimic macular amyloidosis include:

• Lichen planus pigmentosus
• Post-inflammatory hyperpigmentation
• Melasma
• Frictional dermatitis
• Pigmented contact dermatitis

Treatment options

Medical therapies

Treatment is challenging as amyloid deposits do not resolve easily, but therapies can improve pigmentation and reduce itch. Options include:

• Topical corticosteroids – reduce inflammation and pruritus but not long-term pigmentation.
• Topical calcineurin inhibitors (e.g., tacrolimus, pimecrolimus) – safer for long-term itch control.
• Keratolytics (salicylic acid, urea, lactic acid) – help smooth texture and lighten pigmentation.
• Depigmenting agents such as hydroquinone or azelaic acid may be trialled in resistant pigmentation.

Procedural treatments

Several device-based therapies can help reduce pigmentation and improve cosmetic outcome:

• Phototherapy – narrowband UVB has been used in selected patients.
• Fractional CO₂ laser – improves pigmentation and skin texture.
• Q-switched Nd:YAG laser – targets dermal pigmentation.
• Pulsed dye laser – sometimes used when erythema accompanies pigmentation.

Lifestyle and supportive measures

Since friction and scratching worsen macular amyloidosis, lifestyle modification is crucial:

• Avoid back-scratchers, loofahs, or harsh exfoliation.
• Wear soft fabrics such as cotton rather than coarse synthetics or wool.
• Use emollients regularly to reduce skin dryness and itching.
• Control underlying atopic dermatitis or eczema if present.

Prognosis and complications

Macular amyloidosis is benign and does not progress to systemic amyloidosis. However, it is usually chronic and recurrent. The main complications are cosmetic disfigurement and persistent itching, which can lead to psychological distress, sleep disturbance, and secondary lichenification from scratching. Early recognition and management improve outcomes.

Why choose Skinhorizon for macular amyloidosis?

• Consultant dermatologist-led assessment with experience in pigmentary disorders.
• Access to advanced devices including fractional CO₂ laser and Q-switched Nd:YAG.
• Tailored combination treatment plans to reduce pigmentation and manage itch.
• Care delivered under CQC governance with follow-up monitoring.

Your first visit — what to expect

1. History: Onset, duration, itch severity, friction habits, family history, and ethnic background.
2. Examination: Distribution of pigmentation, rippled pattern, dermoscopic evaluation.
3. Discussion: Education about the benign but persistent nature of the condition and available options.
4. Treatment plan: Combination of topical therapy, devices, and lifestyle modification.
5. Follow-up: Reviews to assess itch control, pigmentation fading, and treatment tolerance.

Reviewed by: Dr Mohammad Ghazavi, Consultant Dermatologist
Skinhorizon Clinic, 4 Clarendon Terrace, Maida Vale, London W9 1BZ
Last reviewed: 22 August 2025